Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Studies try to shed light on impact of race

Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year.

3 Jun 2007

Oncolytic viruses deliver a knockout punch to cancers

New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.

11 May 2007

Tarceva extends life of patients with pancreatic cancer

New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.

27 Apr 2007

Oncolytics Biotech researchers demonstrate reovirus/gemcitabine

Oncolytics Biotech announced that a poster by Dr. Maureen E. Lane et al. of Cornell University, New York , entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts" was presented at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, CA.

18 Apr 2007

Early stage pancreatic cancer expresses antigen targeted by Immunomedics' PAM4 antibody

Immunomedics has reported in an oral presentation at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) that the antigen targeted by the humanized PAM4 antibody is expressed in early stage pancreatic cancer specimens, a stage before the tumor becomes invasive.

18 Apr 2007

Curcumin has anticancer effects

Curry powder is a mixture predominantly composed of turmeric root extract and other spices such as coriander and fenugreek.

14 Apr 2007

Massive gene screening points way to more effective chemotherapy

Using a technology that can quickly screen all 20,000-plus human genes for biological activity, scientists have isolated 87 genes that seem to affect how sensitive human cancer cells are to certain chemotherapy drugs.

12 Apr 2007

Trial of new therapy for pancreatic cancer

Patients in Liverpool are to trial a new therapy for pancreatic cancer - a disease which sees most sufferers die within a year of diagnosis.

15 Mar 2007

Squalenoyl nanomedicines as potential therapeutics

Nucleoside analogs such as cytarabine and gemcitabine are powerful anticancer agents, but a simple chemical modification that causes them to assemble into stable nanoparticles could make them even more valuable in the treatment of a wide variety of cancers.

23 Oct 2006

Study: Collecting duct carcinoma

Collecting duct carcinoma is a rare and highly aggressive variant of renal cell carcinoma that frequently presents with advanced disease, has few effective treatment options, and is associated with a poor prognosis.

17 Aug 2006

Combining chemotherapy with radiation therapy after the surgical removal of cancer in the pancreas improves survival

Patients with pancreatic cancer, a historically difficult-to-treat cancer with poor survival rates, may benefit from treatments studied in an international, multi-center research trial.

26 Jul 2006

FDA approval for Gemzar for ovarian cancer

Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Gemzar (gemcitabine HCl) for use in the treatment of women living with recurrent ovarian cancer.

18 Jul 2006

Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial.

9 Jun 2006

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist.

6 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Nicotine and chemotherapy not a good mix

Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.

3 Apr 2006

Capecitabine and Gemcitabine help battle pancreatic cancer

The prognosis of pancreatic cancer is poor but new therapies such as gemcitabine have contributed to improving the outcome for patients. Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients.

3 Nov 2005

Lung cancer drug approved for treating pancreatic cancer

Genentech and OSI Pharmaceuticals have announced that U.S. regulators have approved their lung cancer drug Tarceva for the treatment of pancreatic cancer.

3 Nov 2005

New chemo combo means longer life for pancreatic cancer patients

Pancreatic cancer is one of the most difficult cancers to treat, and has an overall one-year survival rate of only 13%.

3 Nov 2005

First advance in pancreatic cancer treatment in a decade offers new hope

The first advance in pancreatic cancer treatment in a decade has been achieved by researchers in a Canadian-led study, and at last gives some encouragement to scientists and invigorates a field that has experienced more than its share of disheartening failures.

15 May 2005